bone biologics
-
Financial
Bone Biologics Prices $5.0 Million Underwritten Public Offering
BURLINGTON, Mass., June 15, 2023–(BUSINESS WIRE)– Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products…
Read More » -
Biologics
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Company plans to begin 30-patient trial later this year April 11, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a…
Read More » -
Spine
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
January 26, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces…
Read More » -
Biologics
Bone Biologics CEO Issues Letter to Stockholders
BURLINGTON, Mass., October 25, 2022 (BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today…
Read More » -
Spine
Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
Secures rhNELL-1 Carrier for Bone Regeneration Spine Fusion Product March 7, 2022 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer…
Read More » -
Biologics
Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
October 13, 2021 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for…
Read More » -
Biologics
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
January 7, 2020 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis…
Read More » -
Financial
Bone Biologics Completes $5.9 Million of Financing
July 23, 2018 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets,…
Read More » -
Financial
Bone Biologics Completes $500,000 of Financing
March 29, 2018 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets,…
Read More » -
Biologics
Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties
December 20, 2017 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (OTC QB: BBLG), a developer of orthobiologic products for the spinal fusion,…
Read More » -
Spine
Bone Biologics Adds Osteoporosis and Trauma Indications to its Portfolio
August 23, 2017 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp (OTC: BBLG), a developer of orthobiologic products for domestic and international spine…
Read More » -
Financial
Bone Biologics Completes $1.4 Million Round of Financing
August 22, 2017 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets,…
Read More » -
Biologics
Bone Biologics Announces Appointment of Bret Hankey to Company’s Board of Directors
August 03, 2017 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company’s board of…
Read More » -
Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
THOUSAND OAKS, Calif., March 10 /PRNewswire/ — Bone Biologics, Inc. announced today it had received another round of investment for preferred shares…
Read More »